Ensysce Biosciences (NASDAQ:ENSC) stock is in the news today as retail traders take interest in the company with plenty of chatter on social media. Source: Shutterstock The extra attention on ENSC ...
Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage pharmaceutical company dedicated to bringing a novel opioid to the market. ENSC is committed to finding a solution to the opioid crisis plaguing ...
Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing novel opioids that provide the needed pain relief, while greatly limiting the potential for abuse and overdoses that ...
Ensysce Biosciences shares are trading lower by 30% during Thursday's session. The company announced a $5 million registered direct offering and concurrent private placement. Post-Labor Day Trading ...
Ensysce Biosciences Inc (NASDAQ:ENSC) completed PF614-MPAR-101, a clinical study examining the company's first pain medication with overdose protection, PF614-MPAR. The final Part B of the study ...
Ensyce Biosciences (NASDAQ:ENSC) stock is taking a beating on Friday after the clinical-stage biotech company announced $8 million in financing. This financing comes from a private placement with ...
SAN DIEGO, CA / ACCESSWIRE / January 31, 2024/Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Fintel reports that on July 3, 2023, HC Wainwright & Co. initiated coverage of Ensysce Biosciences (NASDAQ:ENSC) with a Buy recommendation. As of June 2, 2023, the average one-year price target for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results